学科建设与科研创新是"杏林红"驱动高质量发展的重要体现。该院传统优势学科骨伤科再次入选国 家级重点专科，中医心病学（心血管内科）则获批浙江省县级中医药特色优势学科建设项目。去年，医 院科研工作取得进展，共完成课题立项43项，其中包括省自然科学基金项目1项、省卫健委课题立项13 项。 在改善患者就医体验和服务社会方面，"杏林红"理念也转化为切实行动。该院着力优化院内环境， 完成了体检中心升级、康复科搬迁新址以及中医综合治疗区扩容。"舒髋健膝走康途"慈善项目在四川康 定落地实施，拓展了服务半径。同时，医院积极推进中医药文化传承，通过打造文化展示区、开展萧然 医派非遗保护工作，让中医药瑰宝焕发时代光彩。 近年来，该院擦亮"杏林红"党建品牌，深化党建与业务的融合，致力于为区域居民提供更优质的医 疗服务。在萧山区审计局的专项审计协同助力下，该院医共体总院构建起"专家下沉、师徒传承、技术 共享、资源辐射"的新型联动体系，推动优质医疗资源实现城乡共享。医院精选40名中医专家担任社区 卫生服务站"名誉站长"，让优质医疗资源下沉基层。目前，医共体内5家社区卫生服务中心已全部建成 中医阁，其中1家为旗舰中医馆。7位名中医在4家中 ...

声明：本系列文章基于原期刊目录和摘要内容整理而得，仅限于读者交流学习。如有侵权，请联系 删除。 期刊介绍 ： 《Journal of Health Economics》（《健康经济学杂志》）是一本专注于健康和医疗保健经济学领域 的学术期刊。该期刊成立于1982年，它涉及的主题包括健康服务的生产和供应、健康服务的需求和 利用、健康服务的融资、健康的决定因素（包括健康投资和风险健康行为）、疾病不良后果、需求 者、供应者和其他卫生保健机构的行为模型、政策干预的评估以及卫生政策的效率和分配等方面。 该刊每年发行6期，平均每期发表文章10篇左右，2024年影响因子为3.4。 本期看点： 医疗成本： ●政府网站逐步公开医疗项目价格，对于手术类项目和影像类检查项目，费用分别下降了5.1%和 9.1%。价格下降主要得益于医疗机构与保险公司之间的协商议价，而非患者的低价搜索行为。 ●当初级保健医生掌握专科医生费用信息并存在经济激励时，向低成本专科医生转诊显著提升。费 用排名每降低一个等级，转诊份额增加4.6个百分点，短期内可降低45%转诊成本，但该行为调整具 有时效约束性（四个月）。 ●基于孟加拉国"女性中学助学金计划"，研究 ...

SINGAPORE, May 27, 2025 (GLOBE NEWSWIRE) -- In a landmark announcement that bridges Asia and Europe, Leo International Group has acquired a controlling stake in SPOABG AG, a publicly listed company on the Frankfurt Stock Exchange (FSE). The company has now been officially renamed Leo International Precision Health AG (LIPH AG), with updated ticker symbols “LEOW.F” and “LEOW.DU”. This momentous move marks the first time in a century that a Taiwanese-founded enterprise has achieved mainboard listing status o ...

Core Viewpoint - Blade Mobility Inc. has seen a significant stock increase of over 18% following the release of its first-quarter earnings, highlighting positive financial performance and growth potential in the air mobility sector [1][3]. Company Overview - Blade Mobility operates in the air transport sector, offering services through a fleet that includes helicopters, private jets, turboprops, and amphibious seaplanes. The business is divided into two main verticals: Medical Services (58% of revenue) and Passenger Services (42% of revenue) [2][3]. Financial Performance - The company reported revenue of $54.3 million, exceeding expectations of $49.3 million, marking a 10% increase. The earnings per share showed a loss of four cents, which was better than the anticipated loss of 11 cents. Notably, Blade achieved its first-ever EBITDA profit of $0.1 million in the passenger segment [3][4]. - Blade reaffirmed its full-year revenue guidance of $245 million to $265 million, indicating a potential 2% year-over-year gain, driven by reduced aircraft maintenance and ongoing cost-saving measures [4]. Market Position and Future Outlook - Blade Mobility went public via a SPAC in 2020 and, despite facing challenges in the past, has shown resilience with a stock recovery from its 52-week low. The recent earnings report has positioned the stock above its 200-day simple moving average, suggesting bullish momentum [5][7]. - The air mobility sector is expanding, with growing interest in eVTOLs. Blade's core business in organ transport provides a significant first-mover advantage, making it less vulnerable to competition from companies like Joby Aviation and Archer Aviation [8]. - Analysts project a 12-month stock price forecast of $6.25, representing an 80.64% upside from the current price of $3.46, with a consensus indicating a bullish sentiment towards the stock [9][10].

Ventas (VTR) Q1 2025 Earnings Call May 01, 2025 10:00 AM ET Company Participants Bill Grant - Investor RelationsDebra Cafaro - Chairman & CEOJustin Hutchens - Executive Vice President, Senior Housing and CIORobert Probst - Executive VP & CFOJames Kammert - Managing DirectorMichael Carroll - Managing Director & Head of US Real Estate ResearchVikram Malhotra - Managing DirectorJeffrey Spector - Managing DirectorRichard Anderson - Managing Director - Equity ResearchOmotayo Okusanya - Managing DirectorJuan Sana ...

Cautionary Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among others, statements of expectations, beliefs, future plans and strategies, anticipated results from operations and developments and other matters that are not historical facts. Forward-looking statements include, among other things, statements ...

Core Insights - Teladoc Health reported a consolidated revenue of $629.4 million for Q1 2025, a decrease of 3% compared to $646.1 million in Q1 2024 [5][6] - The company experienced a net loss of $93.0 million, or $0.53 per share, which is an increase in loss compared to $81.9 million, or $0.49 per share, in the previous year [7][26] - Adjusted EBITDA for Q1 2025 was $58.1 million, down 8% from $63.1 million in Q1 2024 [11][47] Financial Performance - Revenue breakdown: Access fees revenue decreased by 6% to $525.7 million, while other revenue grew by 16% to $103.6 million [6][28] - U.S. revenue decreased by 4% to $525.0 million, while international revenue increased by 6% to $104.4 million [6][28] - Integrated Care segment revenue increased by 3% to $389.5 million, while BetterHelp segment revenue decreased by 11% to $239.9 million [6][32] Loss and Expenses - The net loss included a non-cash goodwill impairment charge of $59.1 million, which contributed significantly to the overall loss [7][9] - Total costs and expenses for Q1 2025 were $749.98 million, compared to $733.25 million in Q1 2024 [26] - Stock-based compensation expense decreased to $25.2 million from $42.3 million in the previous year [27] Cash Flow and Capital Expenditures - Cash flow from operations was $15.9 million, an increase from $8.9 million in Q1 2024 [12] - Capital expenditures were $31.6 million, down from $35.5 million in the previous year [12] Strategic Developments - Teladoc announced the acquisition of UpLift Health Technologies for $30 million, aimed at enhancing its BetterHelp segment [13] - The acquisition is expected to expand access to virtual mental health services for consumers [13] Future Outlook - For the full year 2025, the company expects revenue between $2.468 billion and $2.576 billion, with adjusted EBITDA projected between $263 million and $304 million [16] - The second quarter 2025 outlook includes expected revenue of $614 million to $633 million and adjusted EBITDA of $56 million to $70 million [18]

根据上级要求，淄博市第一医院分院的结核病职能已划转至淄博市传染病医院，现已转型为综合性医院，涵盖综合内科、外科、中 医科、针灸科、眼科等多个专业，为患者提供更优质、全面的医疗服务。 就医环境优美 综合内科：诊治呼吸、消化、心脑血管、神经系统、内分泌系统等疾病，如慢性支气管炎、胃炎、高血压、糖尿病、帕金森等疾 病。 外科：分院新设置大外科门诊，负责普外科、骨伤外科、胸外科、泌尿外科及血管外科常见病的诊断和治疗。可以开展体表肿物切 除、淋巴结活检、痔疮手术、骨折处理。对颈肩痛、腰腿痛、关节痛采取综合治疗，包括药物治疗、神经阻止、痛点封闭、关节腔 注射等各类外科治疗。 针灸科：运用针灸与针刀疗法，治疗脑出血和脑梗塞后遗症、各类神经痛，缓解肩周炎、网球肘及颈腰椎疾病引发的不适。采用针 灸调理消化道和呼吸道疾病，治疗耳鸣和耳聋。专长于面瘫、偏瘫治疗，善用针刀处理各类疼痛疾病。 中医科：结合体质辨识，实施辨证施治。开展针灸、督灸、中药贴敷、耳穴压豆、火龙罐等中医适宜技术服务。提供中药汤方、膏 方等中药传统服务，免费代煎配送到家。 眼科：擅长白内障、眼底病、青光眼诊疗等技术。 医院进行了全面提升改造，整体环境焕然一新，精心 ...